HCV and interferon: viral strategies for evading innate defence mechanisms in the virus-host battle

被引：6

作者：

Capobianchi, MR

Abbate, I

Cappiello, G

Solmone, M

机构：

[1] Natl Inst Infect Dis L Spallanzani, I-00149 Rome, Italy

[2] Sandro Pertini Hosp, Rome, Italy

来源：

CELL DEATH AND DIFFERENTIATION | 2003年 / 10卷 / Suppl 1期

关键词：

D O I：

10.1038/sj.cdd.4401142

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

[No abstract available]

引用

页码：S22 / S24

页数：3

共 21 条

[1] THE INTERFERONS - A BIOLOGICAL SYSTEM WITH THERAPEUTIC POTENTIAL IN VIRAL-INFECTIONS [J].

BARON, S ;

DIANZANI, F .

ANTIVIRAL RESEARCH, 1994, 24 (2-3) :97-110

[2]

Cappiello G, 2001, HEPATOLOGY, V34, p415A

[3] Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro [J].

Castet, V ;

Fournier, C ;

Soulier, A ;

Brillet, R ;

Coste, J ;

Larrey, D ;

Dhumeaux, D ;

Maurel, P ;

Pawlotsky, JM .

JOURNAL OF VIROLOGY, 2002, 76 (16) :8189-8199

[4] Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection [J].

Enomoto, N ;

Sakuma, I ;

Asahina, Y ;

Kurosaki, M ;

Murakami, T ;

Yamamoto, C ;

Ogura, Y ;

Izumi, N ;

Marumo, F ;

Sato, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (02) :77-81

[5] Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein [J].

Gale, MJ ;

Korth, MJ ;

Tang, NM ;

Tan, SL ;

Hopkins, DA ;

Dever, TE ;

Polyak, SJ ;

Gretch, DR ;

Katze, MG .

VIROLOGY, 1997, 230 (02) :217-227

[6]

GRANDVAUX N, 2001, CURR OPIN INFECT DIS, V16, P259

[7] Effect of alpha interferon on the hepatitis C virus replicon [J].

Guo, JT ;

Bichko, VV ;

Seeger, C .

JOURNAL OF VIROLOGY, 2001, 75 (18) :8516-8523

[8] Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway [J].

Heim, MH ;

Moradpour, D ;

Blum, HE .

JOURNAL OF VIROLOGY, 1999, 73 (10) :8469-8475

[9] Management strategies using pharmacogenomics in patients with severe HCV-1b infection: A decision analysis [J].

Moriguchi, H ;

Uemura, T ;

Kobayashi, M ;

Chung, RT ;

Sato, C .

HEPATOLOGY, 2002, 36 (01) :177-185

[10] Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy [J].

Nousbaum, JB ;

Polyak, SJ ;

Ray, SC ;

Sullivan, DG ;

Larson, AM ;

Carithers, RL ;

Gretch, DR .

JOURNAL OF VIROLOGY, 2000, 74 (19) :9028-9038

← 1 2 3 →